CustomerValidation
- •NatMed.2016May;22(5):547-56.
- •MolCell.2017Mar2;65(5):873-884.e8.
- •CellSignal.2016Mar;28(3):148-56.
- •Toxicology.2016May20;355-356:31-38.
- •EnvironToxicol.2017Oct;32(10):2316-2322.
- •HarvardMedicalSchoolLINCSLIBRARY
Description | CHIR-99021isaGSK-3α/βinhibitorwithIC50of10nM/6.7nM;>500-foldselectivityforGSK-3versusitsclosesthomologsCDC2andERK2,aswellasotherproteinkinases. |
---|---|
IC50&Target | IC50:10nM/6.7nM(GSK-3α/β)[1] |
InVitro | CHIR99021inhibitshumanGSK-3βwithKivaluesof9.8nM[1].CHIR99021isasmallorganicmoleculethatinhibitsGSK3αandGSK3βbycompetingfortheirATP-bindingsites.InvitrokinaseassaysrevealthatCHIR99021specificallyinhibitsGSK3β(IC50=~5nM)andGSK3α(IC50=~10nM),withlittleeffectonotherkinases[2].InthepresenceofCHIR-99021theviABIlityoftheES-D3cellsisreducedby24.7%at2.5μM,56.3%at5μM,61.9%at7.5μMand69.2%at10μMCHIR-99021withanIC50of4.9μM[3]. |
InVivo | InZDFrats,asingleoraldoseofCHIR99021(16mg/kgor48mg/kg)rapidlylowersplasmaglucose,withamaximalreductionofnearly150mg/dl3-4hafteradmiNISTration[1].CHIR99021(2mg/kg)givenonce,4hbeforeirrADIation,significantlyimprovessurvivalafter14.5GyaBDominalirradiation(ABI).CHIR99021treatmentsignificantlyblockscryptapoptosisandaccumulationofp-H2AX+cells,andimprovescryptregenerationandvillusheight.CHIR99021treatmentincreasesLgr5+cellsurvivalbyblockingapoptosis,andeffectivelypreventsthereductionofOlfm4,Lgr5andCD44asearlyas4h[4]. |
References |
|
PreparingStockSolutions |
Pleaserefertothesolubilityinformationtoselecttheappropriatesolvent. | ||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
KinaseAssay [2] | KinasesarepurifiedfromSF9cellsthroughuseoftheirHisorGlutag.Glu-taggedproteinsarepurified,andHis-taggedproteinsarepurified.Kinaseassaysareperformedin96-wellplateswithappropriatepeptidesubstratesina300-μLreactionbuffer(variationson50mMTris-HCl,pH7.5,10mMMgCl2,1mMEGTA,1mMdithiothreitol,25mMβ-glycerophosphate,1mMNaF,and0.01%bovineserumalbumin).PeptideshasKmvaluesfrom1to100μM.CHIR99021orCHIRGSKIAisaddedin3.5μLofMe2SO,followedbyATPtoafinalconcentrationof1μM.Afterincubation,triplicate100-μLaliquotsaretransferredtoCombiplate8platescontaining100μL/wellof50μMATPand20mMEDTA.After1hour,thewellsarerinsedfivetimeswithphosphate-bufferedsaline,filledwith200μLofscintillationfluid,sealed,andcountedinascintillationcounter30minlater.Allofthestepsareatroomtemperature.Thepercentageofinhibitioniscalculatedas100×(inhibitor-noenzymecontrol)/(Me2SOcontrol-noenzymecontrol)[2].MCEhasnotindependentlyconfirmedtheaccuracyofthesemethods.Theyareforreferenceonly. | ||||||||||||||||
CellAssay [3] | CHIR99021isdissolvedinDMSOandstored,andthendilutedwithappropriatemediabeforeuse[3]. TheviabilityofthemouseEScellsisdeterminedafterexposuretodifferentconcentrationsofGSK3inhibitorsforthreedaysusingtheMTTassay.ThedecreaseofMTTactivityisareliablemetabolism-basedtestforquantifyingcellviability;thisdecreasecorrelateswiththelossofcellviability.2,000cellsareseededovernightongelatine-coated96-wellplatesinLIF-containingEScellmedium.OnthenextdaythemediumischangedtomediumdevoidofLIFandwithreducedserumandsupplementedwith0.1-1μMBIO,or1-10μMSB-216763,CHIR-99021orCHIR-98014.BasalmediumwithoutGSK3inhibitorsorDMSOisusedascontrol.Alltestedconditionsareanalyzedintriplicates[3].MCEhasnotindependentlyconfirmedtheaccuracyofthesemethods.Theyareforreferenceonly. | ||||||||||||||||
AnimalAdministration [1][4] | CHIR99021isformulatedassolutionsin20mMcitrate-buffered15%CaptisolorasfinesUSPensionsin0.5%carboxymethylcellulose(Rat)[1]. Rat[1] | ||||||||||||||||
References |
|
MolecularWeight | 465.34 | ||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Formula | C₂₂H₁₈Cl₂N₈ | ||||||||||||
CASNo. | 252917-06-9 | ||||||||||||
Storage |
| ||||||||||||
Shipping | RoomtemperatureincontinentalUS;mayvaryelsewhere | ||||||||||||
Solvent&Solubility | DMSO:≥5.1mg/mL *"<1 mg/ml"="" means="" slightly="" soluble="" or="" insoluble.="" "≥"="" means="" soluble,="" but="" saturation="">1> Purity:99.92% 品牌介绍
托烷司琼临床评价药物相关作用适应症托烷司琼CAS号:89565-68-4英文名称:Tropisetron英文同义词:icf205-930;TROPICACID;TROPISETRON;SS-TROPISETRON;BETA-TROPISETRON;Tropisetron(ICS205930);TROPISHTRONHYDROCHLORIDE;Indole-3-carbonylchloride;3-Tropanylindole-3-carboxylate;lαH,5Αh-Tropan-3α-ylindole-3-carboxylate中文名称:托烷司琼中文同义词:托普西隆;托普西龙;曲匹西龙;托烷司琼;Β-托烷司琼;CS-348;Β-内托烷司琼;吲哚-3-甲酰氯;Β-托烷司琼(光学异构体);Β-托烷司琼,托烷司琼异构体CBNumber:CB3236404分子式:C17H20N2O2分子量:284.35MOLFile:89565-68-4.mol化学性质安全信息用途供应商112化学性质安全信息用途供应商112托烷司琼化学性质熔点:201-202°C沸点:448.5±35.0°C(Predicted)密度:1.26储存条件:2-8°C溶解度:H2O:soluble形态:solid酸度系数(pKa):15.38±0.30(Predicted)颜色:whiteCAS数据库:Chemicalbook89565-68-4(CASDataBaseReference)安全信息WGKGermany:3托烷司琼化学药品说明书托烷司琼|药物应用信息托烷司琼性质、用途与生产工艺临床评价Sorbe等报道本品对含顺铂(剂量50~89mg/m2)化疗方案引起的急性呕吐完全控制率为63%。58例恶性肿瘤化疗所致恶心、呕吐者,应用托烷司琼或昂丹司琼8mg分别在同一病人前后2个化疗周期的第1d给药前30min静脉注射,并用地塞米松10mg静脉滴注。结果两药控制急性及迟发性恶心、呕吐的疗效基本相似,均可达81%~100%。本品对强致吐化疗药物顺铂的止吐疗效突出。药物相关作用饮食可略为延长本品的吸收。本品与利福平、苯巴比妥等肝酶诱导药同时使用,可加快代谢,故快代谢型者需增加剂量,慢者则不必。西咪替丁等肝酶抑制药对本品血药浓度无明显影响。适应症托烷司琼临床用于预防和治疗癌症化疗引起的恶心和呕吐。化学性质结晶,熔点201-202℃(二氯甲烷-乙酸乙酯)。单盐酸托烷司琼(TropisetronMonohydroehloride):C17H20N2O2?HCI。[105826-92-4]。熔点283-285℃(分解)。用途有高效性和选择性的5-HT3受体拮抗剂。用于化疗所致的呕吐。用途为5-羟色胺拮抗药生产方法托品醇(I)和酰氯(Ⅱ)反应,可得托烷司琼。托烷司琼上下游产品信息上游原料托品醇下游产品
联络我们
|